Under the agreement, Clinect will be responsible for obtaining marketing authorisation for Qutenza® in Australia and, upon approval, marketing and distributing the product in Australia.
"We firmly believe in the benefits that this non-opioid treatment option can provide to people suffering from peripheral neuropathic pain and continue to work on expanding its footprint to reach more patients worldwide," Jan Adams, Chief Commercial Officer (CCO) at Grünenthal told That's Health.
"Clinect is an experienced specialist with a strong presence in Australia, and I look forward to joining forces with their team to bring our brand to Australia, a major market of the Asia-Pacific region."
"We value the opportunity to work alongside Grünenthal, a global leader in pain management, to introduce Qutenza® to the Australian market,” said Merryn Wallace, General Manager at Clinect. “This agreement reflects our shared commitment to improving patient outcomes and aligns with Clinect’s strategy of partnering with companies who bring truly differentiated therapies to our region."
Grünenthal acquired the global rights to Qutenza® in 2018 as part of its M&A-driven growth strategy. Since 2017, the company has invested more than €2.3 billion in successful M&A transactions, diversifying its portfolio, enhancing its profitability, and driving business growth. Grünenthal continues to expand the footprint of the acquired brands and to create synergies throughout Grünenthal's infrastructure, including manufacturing, supply, logistics, and commercial activities.
In Europe, Qutenza is indicated for the treatment of peripheral neuropathic pain in adults, either alone or in combination with other medicinal products for the treatment of pain. For further information, please visit www.grunenthalhealth.com.
No comments:
Post a Comment